On this interview, Brian T. Helfand, MD, PhD, describes the potential for PSMA-PET imaging to play a job in figuring out the appropriateness of lively surveillance for sufferers with prostate most cancers. Helfand is a urologic oncologist at NorthShore College Well being System in Chicago, Illinois.
Video Transcript:
Wanting on the skill of PSMA-PET imaging into new areas is at all times actually thrilling. I do suppose definitely that the flexibility to estimate the situation and/or extent of a tumor is crucial to lively surveillance. We do know that greater quantity tumors definitely have greater danger of getting extra aggressive illness and definitely, if we knew that sufferers have greater quantity or extra aggressive tumors, they might not be appropriate for lively surveillance. And definitely, whereas most of those research are ongoing, the preliminary information appears to be like promising to say that there could also be a job for a PSMA next-generation imaging within the determination for the appropriateness for lively surveillance. And definitely, when you do have intense bilateral indicators that might not be as applicable as if somebody has a really minimal quantity of radiotracer accumulation or avidity of their prostate. So, the information nonetheless is forthcoming, however I am very excited that this can be a brand new skill to extra appropriately determine sufferers. I feel additionally the promise of mixing numerous these applied sciences, so utilizing PSMA-PET CT imaging with MRI imaging, so I assume it could be PSMA-PET MRI imaging, additionally provides a brand new dimension as properly. We actually must validate the sensitivity and specificity in these settings, however once more, these research are ongoing and seeking to see how they arrive out.
This transcription has been edited for readability.
